(Go: >> BACK << -|- >> HOME <<)

Jump to content

Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m Cleaned up using AutoEd
Line 12: Line 12:
| target = [[α-fetoprotein]]
| target = [[α-fetoprotein]]
<!-- Clinical data -->
<!-- Clinical data -->
| tradename =
| tradename =
| pregnancy_AU =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_US =
| pregnancy_category =
| pregnancy_category =
| legal_AU =
| legal_AU =
| legal_CA =
| legal_CA =
| legal_UK =
| legal_UK =
| legal_US =
| legal_US =
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =
<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =
<!-- Identifiers -->
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
Line 36: Line 36:
| UNII = GJ2416WK6Y
| UNII = GJ2416WK6Y
| ATC_prefix = none
| ATC_prefix = none
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
<!-- Chemical data -->
<!-- Chemical data -->
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y

Revision as of 16:09, 10 February 2023

Yttrium (90Y) tacatuzumab tetraxetan
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetα-fetoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9971N1712O2007S4290Y
Molar mass145 kg/mol
 ☒NcheckY (what is this?)  (verify)

Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

References